Related Experiment Video

Updated: Jul 7, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Pulmonary fibroblasts, an emerging target for anti-obstructive drugs

Kurt Racké1, Susanne Haag, Amit Bahulayan

  • 1Institute of Pharmacology and Toxicology, University of Bonn, Reuterstrabe 2b, 53113, Bonn, Germany. racke.kurt@uni-bonn.de

Naunyn-Schmiedeberg'S Archives of Pharmacology
|February 14, 2008
PubMed

Insights

Muscarinic antagonists may block pro-fibrotic fibroblast effects in airway remodeling, while beta-adrenoceptor agonists inhibit these processes. These mechanisms are key for treating asthma and COPD.

Area of Science:

  • Pulmonary Fibrosis Research
  • Airway Remodeling Mechanisms
  • Pharmacological Interventions in Respiratory Diseases

Background:

  • Fibrotic alterations are integral to airway remodeling in asthma and COPD.
  • Classical anti-obstructive drugs may influence long-term airway remodeling processes.
  • Pulmonary fibroblasts play a crucial role in airway fibrosis.

Purpose of the Study:

  • To review muscarinic and beta-adrenergic effects on pulmonary fibroblasts.
  • To explore the role of these pathways in airway remodeling.
  • To discuss potential therapeutic implications for respiratory diseases.

Main Methods:

  • Literature review of experimental evidence on muscarinic and beta-adrenergic signaling in pulmonary fibroblasts.
  • Analysis of cellular signaling pathways involved in fibroblast modulation.
  • Discussion of the impact of specific drugs like tiotropium.

Main Results:

  • Muscarinic stimulation promotes pro-fibrotic effects in pulmonary fibroblasts.
  • Long-term blockade of muscarinic pathways may offer therapeutic benefits.
  • Beta-adrenoceptor agonists demonstrate anti-fibrotic effects via cyclic adenosine monophosphate (cAMP) activation.
  • Other agents increasing intracellular cAMP also show anti-fibrotic properties.

Conclusions:

  • Muscarinic antagonists, particularly long-acting ones like tiotropium, may counteract pro-fibrotic fibroblast activities.
  • Beta-adrenoceptor agonists and cAMP-elevating agents exhibit anti-fibrotic effects on pulmonary fibroblasts.
  • Understanding these pathways offers insights into novel therapeutic strategies for airway remodeling in respiratory diseases.

More Related Videos

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis05:45

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Published on: January 16, 2026

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Introduction to Fibroblasts01:09

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms: